Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of million people worldwide and posing severe risks of vision loss and blindness. TRS, the Tarsius bio-inspired technology, approaches inflammatory diseases from within the immune system. Tarsius Pharma implements a patented, proprietary new molecule which was developed to 're-engineer' the immune system.
Change text size
- Plain text
- Medium text
- Enlarged text
Color contrast
- Black and white
- High contrast
- Normal contrast
Display
- Large white cursor
- Large black cursor
- Highlight links
- Disable accessibility
- Declaration of Accessibility
